Jiaji G. Chen

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Steven P. Treon, Joshua Gustine, Kirsten Meid et al. · Journal of Clinical Oncology · 2018 · 177 citations · Full text

Medicine, Hematology, Pharmacology +9

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Lian Xu, Nicholas Tsakmaklis, Guang Yang et al. · Blood · 2017 · 138 citations · Full text

Life Sciences, Genetics, Hematology +11

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Guang Yang, Sara J. Buhrlage, Li Tan et al. · Blood · 2016 · 137 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +8

<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

Jorge J. Castillo, Lian Xu, Joshua Gustine et al. · British Journal of Haematology · 2019 · 103 citations · Full text

Medicine, Molecular Genetics, Oncology +6

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia

Zachary R. Hunter, Lian Xu, Guang Yang et al. · Blood · 2016 · 95 citations · Full text

Life Sciences, Genetics, Molecular Biology +14